Clinical trial

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

NCT03809988

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Palbociclib Normalized identity: palbociclibView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Endocrine therapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2019-04-05

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Advanced Breast Cancerunresolved

Hormone Receptor Positive Tumorunresolved

Human Epidermal Growth Factor 2 Negative Carcinoma of Breastunresolved

Interventions

PalbociclibDRUG · verified · RxNorm: palbociclib

Endocrine therapyDRUG

Sponsors & collaborators

MedSIRlead sponsor

Pfizercollaborator

Mapped research locations

ValenciaSpain4 MadridSpain3 BarcelonaSpain3 ParisFrance2 SevilleSpain2 EssenGermany2 ZaragozaSpain2 LondonUnited Kingdom1 MilanItaly1 StrasbourgFrance1 RomaItaly1 BordeauxFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03809988 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.